The impact of public insurance on RRSO for HBOC in Japan: a nationwide data study.

ABSTRACT: In Japan, risk management based on genetic disposition, such as risk-reducing surgery for hereditary breast and ovarian cancer (HBOC), is covered by public insurance only for some cancer patients. However, non-cancer clients are forced to pay a high co-payment. In this study, we examined the impact of risk-reducing salpingo-oophorectomy (RRSO), before and after the April 2020 public insurance coverage, using nationwide data from the Japanese Organization of Hereditary Breast and Ovarian Cancer. The period from March 2006 to March 2020 was defined as before insurance coverage (Pre), and the period from April 2020 to August 2021 was defined as after insurance coverage (Post). In addition, the period from April 2018 to March 2020 was designated as special (short-Pre) to coincide with the post

SUBMITTER: Matsumoto M 

PROVIDER: S-EPMC12289518 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature